Skip to main content

Specialty Pharmacy

  • Biotech regulatory environment has improved, report finds

    SAN FRANCISCO — Biotech companies saw a decline in project delays due to regulations over the past year, as more than half have said insurance coverage and reimbursement issues have become more difficult, according to a new report.

    The 2013 California Biomedical Industry Report — by PwC, the California Healthcare Institute and BayBio — looked at California's biotech industry and how it faired in 2012.

  • Campaign seeks to raise awareness of inflammatory bowel disease

    NEW YORK — An organization focused on inflammatory bowel disease has enlisted a star of "NYPD Blue," "Judging Amy" and "Private Practice" to raise awareness of the condition.

    The Crohn's and Colitis Foundation of America hired actress Amy Brenneman, who has ulcerative colitis, one of two diseases that collectively make up IBD; the other is Crohn's disease. Both conditions are autoimmune diseases that cause discomfort and inflammation of the intestines and require frequent trips to the bathroom.

  • Biogen Idec hopes treatment will be first advance in hemophilia B treatment in 15 years

    WESTON, Mass. — Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.

    The drug maker announced that it had submitted a regulatory application for recombinant factor IX Fc fusion protein, or rFIXFc, which it called the first long-lasting factor IX therapy for hemophilia B.

  • Ernst & Young report forecasts more difficult M&A environment for pharma companies

    SAN FRANCISCO — While pressure to grow will drive more large drug makers to pursue mergers and acquisitions, diminished resources and competition from biotech and specialty pharmaceutical companies will challenge their ability to do so, according to a new report.

  • Mass. governor proposes new compounding pharmacy legislation

    BOSTON — Massachusetts Gov. Deval Patrick has introduced legislation that would give the state government broader power over compounding pharmacies, the governor's office announced.

  • FDA approves new delivery method for MS drug

    NEW YORK — The Food and Drug Administration has approved a new means of administration for a multiple sclerosis drug, the manufacturers said.

    Pfizer and EMD Serono announced the approval of Rebif Rebidose (interferon beta-1a), a single-use auto-injector for self-administering Rebif, used to treat relapsing forms of MS. EMD Serono is the U.S. division of German drug maker Merck KGaA, so-named to avoid confusion with U.S.-based Merck & Co.

  • Giant-Landover donates to local breast cancer group

    LANDOVER, Md. — Ahold banner Giant Food of Landover, Md., donated $37,305 to the Capital Breast Care Center.

    The donation, presented by Giant-Landover public and community relations manager Jamie Miller (center) to Capital Breast Care Center executive director Wanda Lucas (front row, second from right) comes from money collected by the chain during Breast Cancer Awareness Month.

  • Experimental ALS drug fails in trial

    WESTON, Mass. — An experimental drug for Lou Gehrig's disease made by Biogen Idec has failed in a late-stage clinical trial, the drug maker said Thursday.

    Biogen announced results of its phase-3 trial of dexpramipexole in patients with the disease, known technically as amyotrophic lateral sclerosis, or ALS. The drug failed to improve functioning and survival in patients and failed to show efficacy in key secondary endpoints as well, the company said.

X
This ad will auto-close in 10 seconds